Clinical Trial Update: A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, and immunogenicity of Repevax and rLP2086 vaccine given together in adolescents aged 11 to <19; completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Disease
• Neisseria Meningitidis Serogroup Infection

Drugs mentioned

• REPEVAX
• rLP2086 vaccine

Snippet

Sponsor: Pfizer | Conditions: Meningococcal Vaccine, rLP2086 | Phase 2 | Status: COMPLETED | Results posted: 2014-11-26